Teva announced that the Food and Drug Administration (FDA) has approved QNASL (beclomethasone dipropionate) 40mcg for the treatment of nasal symptoms associated with allergic rhinitis in children 4–11 years old. QNASL 40mcg is the first non-aqueous hydrofluoroalkane (HFA) nasal treatment to be approved for use in children as young as 4 years old.
QNASL 40mcg is a lower-dose version of QNASL Nasal Aerosol (80mcg), an intranasal corticosteroid currently available for the treatment of seasonal and perennial allergic rhinitis in patients ≥12 years old.
The safety and efficacy of QNASL 40mcg was based on data from 3 double-blind, placebo-controlled studies that enrolled children ages 4–11 with allergic rhinitis. Study data showed that treatment with QNASL 40mcg resulted in significant nasal allergy symptom relief in children with season and perennial allergic rhinitis vs. placebo. The safety profile of QNASL 40mcg was similar to placebo across all 3 studies.
QNASL 40mcg is expected to be available in February 2015.
For more information call (855) 55-QNASL or visit QNASL.com.